NVAX Novavax Analyst Ratings

On 6/15/2021 Cantor Fitzgerald brokerage Boosted the Price Target from Reduce to Overweight $217.00 to $272.00
On 5/18/2021 JPMorgan Chase & Co. brokerage Reiterated Rating from Overweight to Neutral $285.00 to $161.00
On 5/12/2021 B. Riley brokerage Lowered the Price Target from $365.00 to $286.00
On 5/12/2021 HC Wainwright brokerage Lowered the Price Target from $317.00 to $294.00

My personal price target is $240.

Looking forward to read your opinion.
Coronavirus (COVID-19)coronavirusstockscovid19stockcovidvaccineFundamental AnalysisTechnical IndicatorsnovavaxNVAXnvaxlongTrend Analysisvaccine

Also on:

Disclaimer